ReSeqTB data platform available to public
CPTR is excited to announce the public launch of the ReSeqTB (Relational Sequencing TB Data) platform.
ReSeqTB standardizes, collates and integrates whole genome sequencing data with currently approved drug susceptibility tests, incorporating clinical outcomes when available. Currently, ReSeqTB serves several different stakeholders including diagnostic developers, level 2 and 3 reference laboratories, and the broad research community. Downloadable drug resistance reports along with visualization tools are available as well. Members of the research community interested in accessing the data platform can simply request access via the website.
The ReSeqTB platform provides:
- User-friendly interface designed for non-expert or expert operability
- Access to data beyond the published literature
- Dynamic and iterative updates of new data generated by global surveillance and clinical trials
- Quality controlled genotypic and additional metadata through expert curation
- Validation of next-generation sequencing analysis output by an expert committee
- Standardized criteria and for grading resistance conferring mutations
- Regulatory-compliant analysis pipeline and database architecture
Key features of the ReSeqTB platform:
- A standardized and validated analysis pipeline for variant analyses of MTB NGS data
- Meta data standardization using CDISC: Supports global, platform-independent data standards that enable information system interoperability
- A well-developed legal structure to ensure intellectual property rights and data ownership remain with contributors
- A structured data sharing architecture to restrict access to sensitive or unpublished data sets
Future iterations of the platform will reflect the identified needs of clinicians, national TB programs, and patient advocacy groups. Continuing the develop ReSeqTB as the best possible platform requires ongoing interaction and dialogue with stakeholders in order to better understand their needs, requirements, and data sharing challenges. We urge you to explore the tools and provide feedback.
ReSeqTB is a joint initiative with several partner organizations funded by the Bill & Melinda Gates Foundation, including the Critical Path Institute, FIND, the World Health Organization (WHO), the Stop TB Partnership’s New Diagnostics Working Group, the U.S. Centers for Disease Control and Prevention (Division of Tuberculosis Elimination), and the U.S. National Institute of Allergy and Infectious Disease.
For additional information, contact Marco Schito.
Source: CPTR
